ACE and heart failure: Two groups of START PPO cardiovascular medications had high lift values for mortality: (1) the omission of an antihypertensive for hypertension (STARTA4) provided a lift = 3.56 for mortality and (2) the omission of ACE inhibitors for patients with heart failure/coronary artery disease (STARTA6) provided a lift = 2.38 for mortality.